Two different potential roles have been described for MSCs in the development of triple-negative breast cancer (TNBC) with BRCA1 gene mutation (aka IRIS, for In-frame Reading of BRCA1 Intron 11 Splice variant), which is the most aggressive breast cancer subtype. The gene discussed is BRCA1; the disease is breast cancer.